Brokerages Set AstraZeneca PLC (LON:AZN) Price Target at GBX 6,303.50

Shares of AstraZeneca PLC (LON:AZN - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is GBX 6,303.50 ($83.89).

Several equities analysts have issued reports on the stock. Shore Capital reaffirmed a "buy" rating on shares of AstraZeneca in a report on Tuesday, April 29th. JPMorgan Chase & Co. reaffirmed an "overweight" rating on shares of AstraZeneca in a research report on Wednesday, February 19th. Finally, Berenberg Bank reissued a "buy" rating and set a GBX 140 ($1.86) price target on shares of AstraZeneca in a report on Wednesday, March 26th.

AstraZeneca Stock Down 0.9%

Shares of AZN traded down GBX 92 ($1.22) during trading hours on Friday, hitting £101.80 ($135.48). The company had a trading volume of 1,538,828 shares, compared to its average volume of 16,714,740. AstraZeneca has a one year low of GBX 9,573.51 ($127.41) and a one year high of £133.88 ($178.17). The company has a market capitalization of £195.87 billion, a PE ratio of 27.90, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The company's fifty day moving average price is £108.59 and its two-hundred day moving average price is £109.07.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.